Kiora Pharmaceuticals Files 2024 10-K
Ticker: KPHMW · Form: 10-K · Filed: Mar 25, 2025 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 10-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Kiora Pharma dropped its 2024 10-K. Check financials.
AI Summary
Kiora Pharmaceuticals Inc. filed its 2024 10-K on March 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly known as Eyegate Pharmaceuticals Inc., is based in Encinitas, CA. The filing details its business operations and financial condition, including various series of preferred stock outstanding as of December 31, 2024.
Why It Matters
This filing provides investors with a comprehensive overview of Kiora Pharmaceuticals' financial health and operational status for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Kiora is subject to significant regulatory, clinical, and market risks inherent in drug development and commercialization.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-25 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Kiora Pharmaceuticals Inc. (company) — Filer of the 10-K
- Eyegate Pharmaceuticals Inc. (company) — Former name of Kiora Pharmaceuticals Inc.
- 2024-12-31 (date) — Fiscal year end
- 2025-03-25 (date) — Filing date
- Encinitas, CA (location) — Company headquarters
FAQ
What is the primary business of Kiora Pharmaceuticals Inc.?
Kiora Pharmaceuticals Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When did Kiora Pharmaceuticals Inc. change its name from Eyegate Pharmaceuticals Inc.?
The name change from Eyegate Pharmaceuticals Inc. to Kiora Pharmaceuticals Inc. occurred on August 11, 2006.
What is the SEC file number for Kiora Pharmaceuticals Inc.'s 10-K filing?
The SEC file number is 001-36672.
What is the business address of Kiora Pharmaceuticals Inc.?
The business address is 332 Encinitas Boulevard, Suite 102, Encinitas, CA 92024.
What types of preferred stock does Kiora Pharmaceuticals Inc. have outstanding as of December 31, 2024?
Kiora Pharmaceuticals Inc. has Series A, Series B, Series C, Series D, and Series E Preferred Stock outstanding as of December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 25, 2025 regarding KIORA PHARMACEUTICALS INC (KPHMW).